August Troendle Sells 1,983 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 1,983 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $620.23, for a total transaction of $1,229,916.09. Following the completion of the transaction, the chief executive officer owned 545,217 shares of the company’s stock, valued at $338,159,939.91. This trade represents a 0.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Medpace Trading Up 0.8%

Shares of NASDAQ:MEDP opened at $619.05 on Thursday. The company has a 50 day moving average of $559.49 and a 200 day moving average of $493.31. The stock has a market cap of $17.28 billion, a P/E ratio of 36.29, a P/E/G ratio of 2.74 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the prior year, the company posted $3.10 EPS. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace remains near a potential technical buy point of $628.92 after its July advance. The stock is trading well above its 50-day and 200-day moving averages, indicating sustained momentum. Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
• Positive Sentiment: The company’s latest quarterly results exceeded expectations: adjusted earnings were $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, surpassing forecasts. Fiscal 2026 EPS guidance remains $17.25 to $17.95.
• Positive Sentiment: Institutional investors and hedge funds own approximately 78% of Medpace, and several investment firms have recently increased their positions. Some analysts have also raised price targets, including RBC’s $692 target and Mizuho’s $665 target.
• Neutral Sentiment: Value-focused investors are comparing Medpace with Concentra Group, but the available report does not establish a clear valuation advantage for MEDP. The stock trades at roughly 36 times earnings, with a PEG ratio above 2.7, suggesting investors are already paying a premium for growth. CON vs. MEDP: Which Stock Should Value Investors Buy Now?
• Neutral Sentiment: Reported short interest was zero shares, producing a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering demand or downside pressure.
• Negative Sentiment: Several executives have recently sold shares near $620–$625. CEO August Troendle sold 15,978 shares in two transactions worth approximately $9.97 million, while CFO Kevin Brady sold 3,400 shares valued at about $2.13 million. Although both executives retain shares, the concentration of insider selling could weigh on sentiment. Medpace CEO August Troendle Sells 1,983 Shares
• Negative Sentiment: Analyst opinion remains cautious overall: the consensus rating is “Hold,” and the average price target of $584.18 is below recent trading levels. This may make additional upside more difficult without another earnings or guidance catalyst.

Institutional Trading of Medpace

Hedge funds and other institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC lifted its holdings in shares of Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Medpace in the second quarter worth $296,000. Finally, M&T Bank Corp boosted its position in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the subject of several research analyst reports. TD Cowen lifted their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and upped their target price for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Truist Financial raised their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a research report on Thursday, July 23rd. Finally, Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Medpace has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.